NELVUTAMIG for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 61 adverse event reports in the FDA FAERS database where NELVUTAMIG was used for Malignant melanoma.
Most Reported Side Effects for NELVUTAMIG
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 29 | 10.5% | 6 | 12 |
| Immune-mediated hepatitis | 18 | 6.5% | 2 | 12 |
| Hypothyroidism | 17 | 6.1% | 0 | 6 |
| Immune-mediated enterocolitis | 16 | 5.8% | 5 | 6 |
| Malignant neoplasm progression | 16 | 5.8% | 3 | 6 |
| Colitis | 15 | 5.4% | 1 | 3 |
| Drug ineffective | 14 | 5.1% | 3 | 0 |
| Immune-mediated hepatic disorder | 14 | 5.1% | 0 | 2 |
| Fatigue | 13 | 4.7% | 0 | 3 |
| Immune-mediated myocarditis | 11 | 4.0% | 1 | 8 |
| Diarrhoea | 10 | 3.6% | 0 | 4 |
| Rash | 10 | 3.6% | 0 | 4 |
| Hepatitis | 9 | 3.3% | 0 | 2 |
| Immune-mediated hypophysitis | 9 | 3.3% | 0 | 4 |
| Immune thrombocytopenia | 9 | 3.3% | 0 | 2 |
Other Indications for NELVUTAMIG
Metastatic malignant melanoma (40)
Clear cell renal cell carcinoma (15)
Non-small cell lung cancer (14)
Product used for unknown indication (14)
Hepatocellular carcinoma (13)
Non-small cell lung cancer metastatic (11)
Lung adenocarcinoma (7)
Renal cell carcinoma (7)
Metastatic renal cell carcinoma (6)
Neoplasm malignant (6)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
PEMBROLIZUMAB (3,261)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)